Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

被引：72

作者：

Freeman, Ciara L. ^{[1
]}

Morschhauser, Franck ^{[2
]}

Sehn, Laurie ^{[3
,4
]}

Dixon, Mark ^{[5
,6
]}

Houghton, Richard ^{[5
,6
]}

Lamy, Thierry ^{[7
]}

Fingerle-Rowson, Guenter ^{[8
]}

Wassner-Fritsch, Elisabeth ^{[8
]}

Gribben, John G. ^{[1
]}

Hallek, Michael ^{[9
,10
]}

Salles, Gilles ^{[11
]}

Cartron, Guillaume ^{[12
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, London, England

[2] Univ Lille, Unite Grp Rech Formes Injectables & Technol Assoc, Ctr Hosp Reg Univ Lille, Hematol, Lille, France

[3] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada

[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[5] Roche Prod Ltd, Dept Biostat, Welwyn Garden City AL7 3AY, Herts, England

[6] Roche Prod Ltd, Dept Stat Programming & Anal, Welwyn Garden City AL7 3AY, Herts, England

[7] CHU Rennes, Rennes, France

[8] F Hoffmann La Roche Ltd, Pharma Dev Oncol, Basel, Switzerland

[9] Univ Cologne, Ctr Integrated Oncol, Dept Internal Med, D-50931 Cologne, Germany

[10] Univ Cologne, Cologne Ctr Excellence Cellular Stress Response &, D-50931 Cologne, Germany

[11] Univ Lyon 1, Hosp Civils Lyon, F-69365 Lyon, France

[12] Univ Montpellier, Ctr Hosp Reg Univ, Dept Clin Hematol, F-34059 Montpellier, France

来源：

BLOOD | 2015年 / 126卷 / 24期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIBODY THERAPY; IN-VITRO; RITUXIMAB; THROMBOCYTOPENIA; INTERLEUKIN-6; NEUTROPHILS; EXPRESSION; CELLS; GA101;

D O I：

10.1182/blood-2015-09-670802

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2646 / 2649

页数：4

共 24 条

[1] Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance [J].

Byrd, JC ;

Waselenko, JK ;

Maneatis, TJ ;

Murphy, T ;

Ward, FT ;

Monahan, BP ;

Sipe, MA ;

Donegan, S ;

White, CA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :791-795

[2] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].

Byrd, JC ;

Murphy, T ;

Howard, RS ;

Lucas, MS ;

Goodrich, A ;

Park, K ;

Pearson, M ;

Waselenko, JK ;

Ling, G ;

Grever, MR ;

Grillo-Lopez, AJ ;

Rosenberg, J ;

Kunkel, L ;

Flinn, IW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164

[3] Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study [J].

Cartron, Guillaume ;

de Guibert, Sophie ;

Dilhuydy, Marie-Sarah ;

Morschhauser, Franck ;

Leblond, Veronique ;

Dupuis, Jehan ;

Mahe, Beatrice ;

Bouabdallah, Reda ;

Lei, Guiyuan ;

Wenger, Michael ;

Wassner-Fritsch, Elisabeth ;

Hallek, Michael .

BLOOD, 2014, 124 (14) :2196-2202

[4] Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset [J].

Freeman, Ciara Louise ;

Dixon, Mark ;

Houghton, Richard ;

Humphrey, Kathryn ;

Fingerle-Rowson, Gunter ;

Kreuzer, Karl-Anton ;

Engelke, Anja ;

Hallek, Michael ;

Goede, Valentin .

BLOOD, 2014, 124 (21)

[5] Rituximab-induced thrombocytopenia: a cohort study [J].

Giezen, Thijs J. ;

Mantel-Teeuwisse, Aukje K. ;

ten Berg, Maarten J. ;

Straus, Sabine M. J. M. ;

Leufkens, Hubert G. M. ;

van Solinge, Wouter W. ;

Egberts, Toine C. G. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (03) :256-266

[6] Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study [J].

Goede, V. ;

Fischer, K. ;

Engelke, A. ;

Schlag, R. ;

Lepretre, S. ;

Montero, L. F. C. ;

Montillo, M. ;

Fegan, C. ;

Asikanius, E. ;

Humphrey, K. ;

Fingerle-Rowson, G. ;

Hallek, M. .

LEUKEMIA, 2015, 29 (07) :1602-1604

[7] Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions [J].

Goede, Valentin ;

Fischer, Kirsten ;

Busch, Raymonde ;

Engelke, Anja ;

Eichhorst, Barbara ;

Wendtner, Clemens M. ;

Chagorova, Tatiana ;

de la Serna, Javier ;

Dilhuydy, Marie-Sarah ;

Illmer, Thomas ;

Opat, Stephen ;

Owen, Carolyn J. ;

Samoylova, Olga ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Doehner, Hartmut ;

Langerak, Anton W. ;

Ritgen, Matthias ;

Kneba, Michael ;

Asikanius, Elina ;

Humphrey, Kathryn ;

Wenger, Michael ;

Hallek, Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) :1101-1110

[8] Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab [J].

Golay, Josee ;

Da Roit, Fabio ;

Bologna, Luca ;

Ferrara, Claudia ;

Leusen, Jeanette H. ;

Rambaldi, Alessandro ;

Klein, Christian ;

Introna, Martino .

BLOOD, 2013, 122 (20) :3482-3491

[9] A PHASE-I TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-6 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND THROMBOCYTOPENIA [J].

GORDON, MS ;

NEMUNAITIS, J ;

HOFFMAN, R ;

PAQUETTE, RL ;

ROSENFELD, C ;

MANFREDA, S ;

ISAACS, R ;

NIMER, SD .

BLOOD, 1995, 85 (11) :3066-3076

[10] Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment [J].

Hallek, Michael .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (05) :446-460

← 1 2 3 →